Regenstrief Research Scientist to Lead American Delirium Society for 2023-24 Term
Regenstrief Research Scientist Noll Campbell, PharmD, M.S., has been voted president-elect of the American Delirium Society (ADS) by the board of directors. Dr. Campbell will be installed into office in conjunction with the society’s national conference in June of 2023.
Delirium is a sudden change in brain function leading to confusion and reduced awareness of a person’s surroundings. People in the intensive care unit often experience delirium.
Dr. Campbell’s research is focused on the recognition and measurement of adverse cognitive effects of medications in older adults with acute and chronic cognitive impairment, including delirium and dementia. This work includes the identification and implementation of tools and processes to mitigate the adverse cognitive effects of medications.
“Delirium is a sign of acute brain dysfunction and more common in older adults. It has also been repeatedly associated with long-term cognitive impairment and dementia,” said Dr. Campbell. “It complicates recovery from acute illness, and costs victims, their families and healthcare systems vast amounts of resources. Reducing these costs and complications of delirium would significantly improve the outlook of the aging population.”
Dr. Campbell maintains an active clinical practice as a geriatric pharmacotherapy expert within Eskenazi Health, supporting the translation and implementation of his research into clinical care.
“I’m excited and gratified to be a part of this society and lead the charge toward eradicating delirium through continued research and collaboration with national and international partners committed to improving delirium science,” said Dr. Campbell.
In his role as the society’s president, Dr. Campbell will oversee the society’s programs and guide resources to advance the mission of advocacy for patients and dissemination of research and best practices.
Regenstrief Research Scientist Malaz Boustani, M.D., MPH, was the founding president of ADS. Babar Khan, M.D., M.S., another Regenstrief research scientist, served as the 2019-2020 president. Both Drs. Campbell and Khan are current members of the ADS board of directors.
The mission of ADS is to encourage research, education, quality improvement, advocacy and implementation science to diminish the influence of delirium on short- and long-term health and welfare of patients.
Noll Campbell, PharmD, M.S.
In addition to his role as a research scientist at Regenstrief Institute, Noll Campbell, PharmD, M.S., is an adjunct associate professor of medicine at Indiana University School of Medicine and an associate professor of pharmacy practice at the Purdue University College of Pharmacy.